Drug
Zimlovisertib clinical trials
Also written PF-06650833.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2014
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
11 studies that test it; most in 2015 (2)
| Year | Studies |
|---|---|
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 1 |
| 2019 | 2 |
| 2020 | 2 |
| 2021 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 7
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 10 · Other 1
Often tested with
Tested in the same studies.
PF-06651600 (2) · Contraceptives, Oral (1) · PF-06700841 (1) · Ropsacitinib (1) · Tofacitinib (1)
Studies
Open first, then newest update. How each study uses zimlovisertib is read from its arms, and is right about nine times in ten.
Testing it · 11
- A Study To Estimate The Effect of PF-06650833 On The Pharmacokinetics (PK) of Oral Contraceptive (OC)CompletedPhase 1PfizerNCT05064332Written as PF-06650833
- A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis SuppurativaCompletedPhase 2PfizerNCT04092452Written as PF-06650833
- TO ASSESS THE EFFICACY AND SAFETY OF PF-06650833, PF-06651600, AND TOFACITINIB ALONE AND IN COMBINATION IN PARTICIPANTS WITH ACTIVE RHEUMATOID ARTHRITIS WITH AN INADEQUATE RESPONSE TO METHOTREXATECompletedPhase 2PfizerNCT04413617Written as PF-06650833
- IRAK4 Inhibition in Treatment of COVID-19 With ARDS (I-RAMIC)TerminatedPhase 2Yale UniversityNCT04575610Written as PF-06650833
- A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTSCompletedPhase 1PfizerNCT03827668Written as PF-06650833 alone
- Safety and Efficacy of Pf-06650833 In Subjects With Rheumatoid Arthritis, With An Inadequate Response To MethotrexateCompletedPhase 2PfizerNCT02996500Written as PF-06650833
- Bioavailability and Food Effect Study of Two Formulations of PF-06650833CompletedPhase 1PfizerNCT03308110Written as PF-06650833
- Study for MR Formulation of PF-06650833 in Healthy Adult Japanese SubjectsCompletedPhase 1PfizerNCT02936154Written as PF-06650833
- Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy SubjectsCompletedPhase 1PfizerNCT02485769Written as PF-06650833
- Study to Evaluate Pharmacokinetics of A Modified Release Formulation of PF-06650833 in Healthy SubjectsCompletedPhase 1PfizerNCT02609139Written as PF-06650833
- Study to Evaluate Safety and Tolerability of Single Ascending Doses of Multiple Formulations of PF-06650833 in Healthy Subjects Under Fasted and Fed ConditionsCompletedPhase 1PfizerNCT02224651Written as PF-06650833
As the comparator · 1 — what is tested is compared with zimlovisertib
Codes
What other systems call zimlovisertib · ClinicalTrials.gg INT000764
- UNII (FDA) S3F315JJXIZIMLOVISERTIBConfirmed FDA, NLM
- NCI Thesaurus C185226ZimlovisertibOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | S3F315JJXI | ZIMLOVISERTIB | Confirmed FDA, NLM |
| NCI Thesaurus | C185226 | Zimlovisertib | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.